126 research outputs found
Whatās So Great About a Trial Anyway? A Reply to Judge Higginbothamās Eldon B. Mahon Lecture of October 27, 2004
United States Circuit Judge Patrick E. Higginbotham, in his October 2004 Eldon B. Mahon lecture at the Bass Hall in Fort Worth, once again identified and criticized a phenomenon in American jurisprudence that has been of great concern to him for several years. Judge Higginbotham\u27s identification of and take on this development can be fairly summarized by referring to the title of a similar lecture he delivered at Loyola University School of Law, which was published in the Fall 2002 SMU Law Review: So Why Do We Call Them Trial Courts? My reply today, entitled What\u27s So Great About a Trial Anyway?, is an effort, and a risky one on my part given his status as compared to mine, to join issue with my friend and colleague on the bench on whether the decline in trials in America, and especially in federal district court, is a positive or a negative development, or, perhaps something in between
The hullaballoo over e-learning? Technology and pluralism in economics
E-learning vs. ātalk and chalkā: this binary opposition presents a conflict that has dominated existing pedagogical research. That technological innovation offers an alternative for pressured educationists to improve efficiency and question the cost-effectiveness of traditional teaching methods creates a false dichotomy. This paper addresses the influence of the erroneous āeither/orā position and discards it. It claims that there is no fundamental antagonism between the two methods of instruction and proffers the alternative found in blended learning methods. The meticulous splicing of e-learning and traditional lectures liberates the Economics lecturer to deliver a pluralist perspective. Thus, technology becomes a vital tool enabling educators to escape from the limitation of monist teaching methods and guarantees that economics students can fully engage with the disciplineās vibrant debates. āContest and controversy; orthodoxy and heterodoxy; critique and rejectā: technologyās real role is to facilitate a workable space for the free thinking mind
Recommended from our members
The Microglial Sensome Revealed by Direct RNA Sequencing
Microglia, the principal neuroimmune sentinels of the brain, continuously sense changes in their environment and respond to invading pathogens, toxins and cellular debris. Microglia exhibit plasticity and can assume neurotoxic or neuroprotective priming states that determine their responses to danger. We used direct RNA sequencing, without amplification or cDNA synthesis, to determine the quantitative transcriptomes of microglia of healthy adult and aged mice. We validated our findings by fluorescent dual in-situ hybridization, unbiased proteomic analysis and quantitative PCR. We report here that microglia have a distinct transcriptomic signature and express a unique cluster of transcripts encoding proteins for sensing endogenous ligands and microbes that we term the āsensomeā. With aging, sensome transcripts for endogenous ligand recognition are downregulated, whereas those involved in microbe recognition and host defense are upregulated. In addition, aging is associated with an overall increase in expression of microglial genes involved in neuroprotection
Scara1 deficiency impairs clearance of soluble Amyloid-Ī² by mononuclear phagocytes and accelerates Alzheimerās-like disease progression
In Alzheimerās disease soluble amyloid beta (sAĪ²) causes synaptic dysfunction and neuronal loss. Receptors involved in clearance of sAĪ² are not known. Here we use shRNA screening and identify the scavenger receptor Scara1 as a receptor for sAĪ² expressed on myeloid cells. To determine the role of Scara1 in clearance of sAĪ² in vivo, we cross Scara1 null mice with PS1-APP mice, a mouse model of Alzheimerās disease and generate PS1-APP- Scara1-deficient mice. Scara1 deficiency markedly accelerates AĪ² accumulation leading to increased mortality. In contrast, pharmacological upregulation of Scara1 expression on mononuclear phagocytes increases AĪ² clearance. This approach is a potential treatment strategy for Alzheimerās disease
Recommended from our members
Scara1 deficiency impairs clearance of soluble Amyloid-Ī² by mononuclear phagocytes and accelerates Alzheimerās-like disease progression
In Alzheimerās disease soluble amyloid beta (sAĪ²) causes synaptic dysfunction and neuronal loss. Receptors involved in clearance of sAĪ² are not known. Here we use shRNA screening and identify the scavenger receptor Scara1 as a receptor for sAĪ² expressed on myeloid cells. To determine the role of Scara1 in clearance of sAĪ² in vivo, we cross Scara1 null mice with PS1-APP mice, a mouse model of Alzheimerās disease and generate PS1-APP- Scara1-deficient mice. Scara1 deficiency markedly accelerates AĪ² accumulation leading to increased mortality. In contrast, pharmacological upregulation of Scara1 expression on mononuclear phagocytes increases AĪ² clearance. This approach is a potential treatment strategy for Alzheimerās disease
An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues
Transfer of T cells to freshly irradiated allogeneic recipients leads to their rapid recruitment to nonlymphoid tissues, where they induce graft-versus-host disease (GVHD). In contrast, when donor T cells are transferred to established mixed chimeras (MCs), GVHD is not induced despite a robust graft-versus-host (GVH) reaction that eliminates normal and malignant host hematopoietic cells. We demonstrate here that donor GVH-reactive T cells transferred to MCs or freshly irradiated mice undergo similar expansion and activation, with similar up-regulation of homing molecules required for entry to nonlymphoid tissues. Using dynamic two-photon in vivo microscopy, we show that these activated T cells do not enter GVHD target tissues in established MCs, contrary to the dogma that activated T cells inevitably traffic to nonlymphoid tissues. Instead, we show that the presence of inflammation within a nonlymphoid tissue is a prerequisite for the trafficking of activated T cells to that site. Our studies help to explain the paradox whereby GVH-reactive T cells can mediate graft-versus-leukemia responses without inducing GVHD in established MCs
CD36 Mediates the Innate Host Response to Ī²-Amyloid
Accumulation of inflammatory microglia in Alzheimer's senile plaques is a hallmark of the innate response to Ī²-amyloid fibrils and can initiate and propagate neurodegeneration characteristic of Alzheimer's disease (AD). The molecular mechanism whereby fibrillar Ī²-amyloid activates the inflammatory response has not been elucidated. CD36, a class B scavenger receptor, is expressed on microglia in normal and AD brains and binds to Ī²-amyloid fibrils in vitro. We report here that microglia and macrophages, isolated from CD36 null mice, had marked reductions in fibrillar Ī²-amyloidāinduced secretion of cytokines, chemokines, and reactive oxygen species. Intraperitoneal and stereotaxic intracerebral injection of fibrillar Ī²-amyloid in CD36 null mice induced significantly less macrophage and microglial recruitment into the peritoneum and brain, respectively, than in wild-type mice. Our data reveal that CD36, a major pattern recognition receptor, mediates microglial and macrophage response to Ī²-amyloid, and imply that CD36 plays a key role in the proinflammatory events associated with AD
Recommended from our members
The scavenger receptor SCARF1 mediates apoptotic cell clearance and prevents autoimmunity
Clearance of apoptotic cells is critical for control of tissue homeostasis however the full range of receptor(s) on phagocytes responsible for recognition of apoptotic cells remains to be identified. Here we show that dendritic cells (DCs), macrophages and endothelial cells use scavenger receptor type F family member 1 (SCARF1) to recognize and engulf apoptotic cells via C1q. Loss of SCARF1 impairs uptake of apoptotic cells. Consequently, in SCARF1-deficient mice, dying cells accumulate in tissues leading to a lupus-like disease with the spontaneous generation of autoantibodies to DNA-containing antigens, immune cell activation, dermatitis and nephritis. The discovery of SCARF1 interactions with C1q and apoptotic cells provides insights into molecular mechanisms involved in maintenance of tolerance and prevention of autoimmune disease
Identification of Unique MicroRNA Signature Associated with Lupus Nephritis
MicroRNAs (miRNA) have emerged as an important new class of modulators of gene expression. In this study we investigated miRNA that are differentially expressed in lupus nephritis. Microarray technology was used to investigate differentially expressed miRNA in peripheral blood mononuclear cells (PBMCs) and Epstein-Barr Virus (EBV)-transformed cell lines obtained from lupus nephritis affected patients and unaffected controls. TaqMan-based stem-loop real-time polymerase chain reaction was used for validation. Microarray analysis of miRNA expressed in both African American (AA) and European American (EA) derived lupus nephritis samples revealed 29 and 50 differentially expressed miRNA, respectively, of 850 tested. There were 18 miRNA that were differentially expressed in both racial groups. When samples from both racial groups and different specimen types were considered, there were 5 primary miRNA that were differentially expressed. We have identified 5 miRNA; hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested. Hsa-miR-371-5P, hsa-miR-1224-3P and hsa-miR-423-5P, are reported here for the first time to be associated with lupus nephritis. Our work establishes EBV-transformed B cell lines as a useful model for the discovery of miRNA as biomarkers for SLE. Based on these findings, we postulate that these differentially expressed miRNA may be potential novel biomarkers for SLE as well as help elucidate pathogenic mechanisms of lupus nephritis. The investigation of miRNA profiles in SLE may lead to the discovery and development of novel methods to diagnosis, treat and prevent SLE
- ā¦